CSL Behring

CSL Behring is a global biotechnology company that develops and delivers innovative biotherapies and influenza vaccines to protect public health and help people with life-threatening medical conditions live full lives. As a subsidiary of the CSL Limited group, CSL Behring's focus is on the development of products to treat coagulation disorders, primary immune deficiencies, hereditary angioedema, neurological disorders, and inherited respiratory disease, among other serious medical conditions.

History

CSL Behring traces its roots back to the establishment of the Commonwealth Serum Laboratories (CSL) in Australia in 1916, as a response to the country's need for self-sufficiency in the production of vital medicines. Over the years, CSL has grown from a national entity into a global biopharmaceutical company. In 2007, CSL Limited rebranded its plasma products division as CSL Behring, reflecting its commitment to providing life-saving therapies derived from human plasma.

Products and Services

CSL Behring offers a wide range of products that include plasma-derived therapies and recombinant products. These therapies are used in the treatment of various conditions such as:

• Hemophilia: CSL Behring produces coagulation factor products for the treatment of hemophilia A and B.
• Immune Deficiencies: The company provides immunoglobulin therapies for individuals with primary and secondary immune deficiencies.
• Hereditary Angioedema: CSL Behring offers treatments for managing and preventing hereditary angioedema attacks.
• Specialty Products: This includes products for the treatment of neurological disorders and inherited respiratory diseases.

CSL Behring is also involved in the research and development of new therapies, with a strong pipeline of products aimed at addressing unmet medical needs.

Research and Development

Research and development (R&D) are central to CSL Behring's mission. The company invests heavily in R&D to improve existing therapies and to discover new treatments. CSL Behring's R&D efforts are focused on the areas of immunology, hematology, cardiovascular and metabolic diseases, respiratory diseases, and transplant therapy.

Global Presence

With its headquarters in King of Prussia, Pennsylvania, USA, CSL Behring operates in more than 30 countries around the world. The company's global reach allows it to serve patients and healthcare professionals with cutting-edge therapies and ensures that its products are accessible to those in need.

Corporate Responsibility

CSL Behring is committed to corporate responsibility, with a focus on patient access to therapies, environmental sustainability, and ethical business practices. The company supports patient organizations and initiatives that aim to improve the quality of life for people with rare and serious diseases.

Conclusion

CSL Behring plays a crucial role in the biotechnology industry, providing essential therapies for patients with rare and serious conditions. Through its commitment to innovation, global presence, and corporate responsibility, CSL Behring continues to make a significant impact on public health and individual lives around the world.